Myoglobin facilitates angiotensin II-induced constriction of renal afferent arterioles. 2017

Z Z Liu, and S Mathia, and T Pahlitzsch, and I C Wennysia, and P B Persson, and E Y Lai, and A Högner, and M Z Xu, and R Schubert, and C Rosenberger, and A Patzak
Institute of Vegetative Physiology, Berlin, Germany.

Vasoconstriction plays an important role in the development of acute kidney injury in rhabdomyolysis. We hypothesized that myoglobin enhances the angiotensin II (ANG II) response in afferent arterioles by increasing superoxide and reducing nitric oxide (NO) bioavailability. Afferent arterioles of C57Bl6 mice were isolated perfused, and vasoreactivity was analyzed using video microscopy. NO bioavailability, superoxide concentration in the vessel wall, and changes in cytosolic calcium were measured using fluorescence techniques. Myoglobin treatment (10-5 M) did not change the basal arteriolar diameter during a 20-min period compared with control conditions. NG-nitro-l-arginine methyl ester (l-NAME, 10-4 M) and l-NAME + myoglobin reduced diameters to 94.7 and 97.9% of the initial diameter, respectively. Myoglobin or l-NAME enhanced the ANG II-induced constriction of arterioles compared with control (36.6 and 34.2%, respectively, vs. 65.9%). Norepinephrine responses were not influenced by myoglobin. Combined application of myoglobin and l-NAME further facilitated the ANG II response (7.0%). Myoglobin or l-NAME decreased the NO-related fluorescence in arterioles similarly. Myoglobin enhanced the superoxide-related fluorescence, and tempol prevented this enhancement. Tempol also partly prevented the myoglobin effect on the ANG II response. Myoglobin increased the fura 2 fluorescence ratio (cytosolic calcium) during ANG II application (10-12 to 10-6 M). The results suggest that the enhanced afferent arteriolar reactivity to ANG II is mainly due to a myoglobin-induced increase in superoxide and associated reduction in the NO bioavailability. Signaling pathways for the augmented ANG II response include enhanced cytosolic calcium transients. In conclusion, myoglobin may contribute to the afferent arteriolar vasoconstriction in this rhabdomyolysis model.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009211 Myoglobin A conjugated protein which is the oxygen-transporting pigment of muscle. It is made up of one globin polypeptide chain and one heme group.
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D003497 Cyclic N-Oxides Heterocyclic compounds in which an oxygen is attached to a cyclic nitrogen. Heterocyclic N-Oxides,Cyclic N Oxides,Heterocyclic N Oxides,N Oxides, Cyclic,N-Oxides, Cyclic,N-Oxides, Heterocyclic,Oxides, Cyclic N
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Z Z Liu, and S Mathia, and T Pahlitzsch, and I C Wennysia, and P B Persson, and E Y Lai, and A Högner, and M Z Xu, and R Schubert, and C Rosenberger, and A Patzak
May 1988, The American journal of physiology,
Z Z Liu, and S Mathia, and T Pahlitzsch, and I C Wennysia, and P B Persson, and E Y Lai, and A Högner, and M Z Xu, and R Schubert, and C Rosenberger, and A Patzak
January 2004, American journal of nephrology,
Z Z Liu, and S Mathia, and T Pahlitzsch, and I C Wennysia, and P B Persson, and E Y Lai, and A Högner, and M Z Xu, and R Schubert, and C Rosenberger, and A Patzak
January 1982, Histochemistry,
Z Z Liu, and S Mathia, and T Pahlitzsch, and I C Wennysia, and P B Persson, and E Y Lai, and A Högner, and M Z Xu, and R Schubert, and C Rosenberger, and A Patzak
August 1997, The American journal of physiology,
Z Z Liu, and S Mathia, and T Pahlitzsch, and I C Wennysia, and P B Persson, and E Y Lai, and A Högner, and M Z Xu, and R Schubert, and C Rosenberger, and A Patzak
December 1994, Japanese journal of pharmacology,
Z Z Liu, and S Mathia, and T Pahlitzsch, and I C Wennysia, and P B Persson, and E Y Lai, and A Högner, and M Z Xu, and R Schubert, and C Rosenberger, and A Patzak
November 2004, Kidney international,
Z Z Liu, and S Mathia, and T Pahlitzsch, and I C Wennysia, and P B Persson, and E Y Lai, and A Högner, and M Z Xu, and R Schubert, and C Rosenberger, and A Patzak
July 2023, International journal of molecular sciences,
Z Z Liu, and S Mathia, and T Pahlitzsch, and I C Wennysia, and P B Persson, and E Y Lai, and A Högner, and M Z Xu, and R Schubert, and C Rosenberger, and A Patzak
January 2020, Kidney & blood pressure research,
Z Z Liu, and S Mathia, and T Pahlitzsch, and I C Wennysia, and P B Persson, and E Y Lai, and A Högner, and M Z Xu, and R Schubert, and C Rosenberger, and A Patzak
April 2007, American journal of physiology. Renal physiology,
Z Z Liu, and S Mathia, and T Pahlitzsch, and I C Wennysia, and P B Persson, and E Y Lai, and A Högner, and M Z Xu, and R Schubert, and C Rosenberger, and A Patzak
December 1994, Kidney international,
Copied contents to your clipboard!